Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease

Background and aims: The clinical course of inflammatory bowel disease is characterised by a succession of relapses and remissions. The aim of our study was to assess whether the predictive value of faecal calprotectin—a non-invasive marker of intestinal inflammation—for clinical relapse is differen...

Full description

Saved in:
Bibliographic Details
Published in:Gut 2005-03, Vol.54 (3), p.364-368
Main Authors: Costa, F, Mumolo, M G, Ceccarelli, L, Bellini, M, Romano, M R, Sterpi, C, Ricchiuti, A, Marchi, S, Bottai, M
Format: Article
Language:English
Subjects:
Adult
Biomarkers - analysis
C reactive protein
calprotectin
CDAI
Colitis, Ulcerative - diagnosis
Colitis, Ulcerative - metabolism
Crohn Disease - diagnosis
Crohn Disease - metabolism
Crohn's disease
Crohn’s disease activity index
CRP
Endoscopy
Epidemiologic Methods
erythrocyte sedimentation rate
ESR
Feces - chemistry
Female
Granulocytes
Humans
IBD
Inflammation
Inflammatory Bowel Disease
intestinal inflammation
Laboratories
Leukocyte L1 Antigen Complex - analysis
Male
Middle Aged
negative predictive value
NPV
Patients
positive predictive value
PPV
Prognosis
receiver operating characteristic
Recurrence
Remission Induction
ROC
Surgery
UCAI
ulcerative colitis
ulcerative colitis activity index
Variables
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and aims: The clinical course of inflammatory bowel disease is characterised by a succession of relapses and remissions. The aim of our study was to assess whether the predictive value of faecal calprotectin—a non-invasive marker of intestinal inflammation—for clinical relapse is different in ulcerative colitis (UC) and Crohn’s disease (CD). Methods: Seventy nine consecutive patients with a diagnosis of clinically quiescent inflammatory bowel disease (38 CD and 41 UC) were followed for 12 months, undergoing regular clinical evaluations and blood tests. A single stool sample was collected at the beginning of the study from each patient and the calprotectin concentration was assessed by a commercially available enzyme linked immunoassay. Results: In CD, median calprotectin values were 220.1 μg/g (95% confidence interval (CI) 21.7–418.5) in those patients who relapsed during follow up, and 220.5 μg/g (95% CI 53–388) in non-relapsing patients (p = 0.395). In UC, median calprotectin values were 220.6 μg/g (95% CI 86–355.2) and 67 μg/g (95% CI 15–119) in relapsing and non-relapsing patients, respectively (p
ISSN:0017-5749
1468-3288
1458-3288
DOI:10.1136/gut.2004.043406